A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
A Phase 1b Randomized, Open Label, Active-Controlled Study to Assess the Safety, Viral Kinetics, and Anti-HBV Activity of GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B (CHB) Infection
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Victoria
-
Melborne, Victoria, Australia, 03168
- Monash Medical Centre
-
Melbourne, Victoria, Australia, 3084
- Austin Health
-
Melbourne, Victoria, Australia, 3004
- Alfred Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Linear Clinical Research Ltd
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z2C9
- Downtown Infectious Diseases Clinic (University of British Columbia)
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H8L6
- The Ottawa Hospital, General Campus
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3P3P1
- Algorithme Pharma
-
St. Romuald, Quebec, Canada, G6W 8H1
- Pro-Recherche
-
-
-
-
-
Auckland, New Zealand, 1042
- Auckland Clinical Studies
-
-
-
-
-
Birmingham, United Kingdom, B152TH
- University Hospitals Birmingham NHS Foundation Trust
-
London, United Kingdom, E1 1BB
- Grahame Hayton Unit
-
London, United Kingdom, NW1-2BU
- University College London Hospital
-
London, United Kingdom, SE5 9RS
- Institute of Liver Studies, King's College Hospital
-
Nottingham, United Kingdom, NG7 2UH
- Nottingham University Hospitals NHS Trust - Queens Medical Centre
-
-
-
-
California
-
San Diego, California, United States, 92105
- Research and Education Inc.
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Institute of Human Virology
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine - St. Luke's Episcopal Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be between 18 and 65 years of age
- Must have Screening plasma HBV DNA ≥ 2x10^3 IU/mL
- Must have chronic HBV infection for at least 6 months
- Must have estimated creatinine clearance (CLCr) ≥ 70 mL/min
- Not pregnant or nursing
- Women must be of non-childbearing potential OR of childbearing potential with confirmed negative pregnancy tests
- Consistent and correct use of recommended methods of birth control for men and women
Exclusion Criteria:
- Pregnant or lactating subjects
- Receipt of anti-HBV nucleoside/nucleotide therapy. Subjects who have failed prior Interferon treatment, greater than 6 months prior to screening, are permitted to participate in the study screening
- Known co-infection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)
- Presence of autoimmune disorders
- History of liver disease other than Hepatitis B
- History of Gilbert's Disease
- Any sign of decompensated liver disease
- Known or suspected cirrhosis
- Evidence of hepatocellular carcinoma
- Presence or history of cardiovascular disease, cardiomyopathy, and/or cardiac conduction abnormalities
- Electrolyte abnormalities
- History of treatment that permanently alters the gastric condition
- Alcohol or substance abuse
- History of bleeding diathesis
- Significant bone disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: GS-7340 8mg
After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
|
Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
|
|
Experimental: GS-7340 25mg
After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
|
Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
|
|
Experimental: GS-7340 40mg
After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
|
Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
|
|
Experimental: GS-7340 120mg
After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
|
Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
|
|
Experimental: Tenofovir disoproxil fumarate 300mg
After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
|
Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in serum hepatitis B virus (HBV) DNA
Time Frame: Up to Week 4
|
Time-weighted average change from baseline through Week 4 (DAVG4) in serum HBV DNA (log10 IU/mL) for GS-7340 8-, 25-, 40 and 120-mg.
|
Up to Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HBV DNA for tenofovir disoproxil fumarate (TDF)
Time Frame: Up to Week 4
|
Comparing the short-term antiviral activity of GS-7340 with TDF 300mg.
This is measured by time-weighted average change from baseline through Week 4 (DAVG4) in serum HBV DNA (log10 IU/mL) for TDF.
|
Up to Week 4
|
|
Change in HBV DNA of GS-7340 through 28 days of therapy
Time Frame: Up to week 4
|
Time weighted change from baseline to day 29 (DAVG4) in serum HBV DNA (log10 IU/mL)
|
Up to week 4
|
|
Pharmacokinetics (PK) of GS-7340 and/or tenofovir (TVF) following single and multiple doses of GS-7340 and TDF
Time Frame: Up to week 4
|
GS-7340 and tenofovir (TFV) PK parameters in plasma will be calculated as applicable: Cmax, Tmax, Clast, Tlast, T1/2, λz, AUC0-t, AUC0-last, AUC0-∞, %AUCexp. PK samples are collected on:
|
Up to week 4
|
|
Safety and Tolerability of Therapy
Time Frame: Up to week 4
|
Safety and tolerability is measured by the incidence of adverse events and graded laboratory abnormalities
|
Up to week 4
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: John Flaherty, MD, Gilead Sciences
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
Other Study ID Numbers
Other Study ID Numbers
- GS-US-320-0101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.